CLL Expert Perspectives on Current and Future Patient Care
CLL Expert Perspectives on Current and Future Patient Care from Patient Empowerment Network on Vimeo.
How does the current day and the future of chronic lymphocytic leukemia (CLL) care look? Experts Dr. Jennifer Brown from Dana-Farber Cancer Institute and Dr. Callie Coombs from the University of California, Irvine discuss drug therapies, mutation profile, and quality of life in CLL patient care.
Download Resource Guide | Descargar guía de recursos
Related Resources:
How Can CLL HCPs Gain More Understanding of Mutation Profiles? |
CLL Expert Updates on Diagnostic Tool and Technology Advances |
CLL Clinical Trials for Molecularly Defined Patient Subgroups |
Transcript:
Dr. Nicole Rochester:
I have really enjoyed this conversation, and I’d like to get closing thoughts from each of you. So I’ll start with you, Dr. Coombs. What is the most important takeaway message you’d like to leave with healthcare professionals who may be listening as they watch this program and understand better about CLL mutations, clinical trials, and managing side effects?
Dr. Callie Coombs:
So what is the most important thing, there’s so many, I would just say CLL is a chronic disease that affects our primarily elderly patients, and so it’s a marathon, not a sprint. However, with all of the advances that we’ve had in excellent drug therapies, despite these resistance mutations, patients can attain many, many, many years of high quality of life. But it’s incumbent upon us as their providers to help ensure that quality of life through effective management of side effects that may be encountered over the course of their time on therapy for the patients that do need therapy.
Dr. Nicole Rochester:
Wonderful. Thank you, Dr. Coombs. And, Dr. Brown, what closing thoughts do you have for our audience today?
Dr. Jennifer Brown:
Well, I would echo what Dr. Coombs said, and I would add that as part of that long marathon of CLL, understanding the mutation profile of patients both at baseline, as we discussed with p53 aberration and IGHV, that really describes how their disease is going to behave over that whole marathon. When they’re on treatment, when they’re not on treatment, and it will just help us help you and the patient understand what to expect and help assist with treatment choice. And so adding in that type of evaluation as we discussed will be very helpful.
